A failure of Can-Fite Biopharma Ltd.'s lead candidate to achieve what the company called "any real effect" over placebo in patients with moderate-to-severe plaque psoriasis sent shares (NYSE:CANF) tumbling more that 60 percent to a 52-week low on Monday before closing at $2.20.